PFBT
PSTX

Parkside Financial Bank & Trust’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Parkside Financial Bank & Trust’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,200
Closed -$11K – 2061
2022
Q3 		$11K Buy
3,200
+1,200
+60% +$3.97K ﹤0.01% 982
2022
Q2 		$5K Hold
2,000
– – ﹤0.01% 1274
2022
Q1 		$9K Buy
+2,000
New +$9.02K ﹤0.01% 1083

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Parkside Financial Bank & Trust's PSTX Position: Q4 2022 in Review

Parkside Financial Bank & Trust sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2022, closing a stake of 3,200 shares — an estimated $11K sold.

Parkside Financial Bank & Trust first reported a position in PSTX in Q1 2022 and held it in 3 quarters. The position peaked at $11K in Q3 2022. 89 funds tracked by Wall St. Rank hold PSTX as of Q4 2022.

  • Parkside Financial Bank & Trust reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Parkside Financial Bank & Trust sold 3,200 Poseida Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $11K.
  • Parkside Financial Bank & Trust first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • Parkside Financial Bank & Trust's Poseida Therapeutics, Inc. Common Stock position peaked at $11K in Q3 2022.
  • 89 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Parkside Financial Bank & Trust's 13F filing for Q4 2022, filed 14 Feb 2023.